Lynx1 Capital Management LP Cabaletta Bio, Inc. Transaction History

Lynx1 Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.22 - $18.82 $3.55 Million - $9.26 Million	492,103 New	492,103 $3.68 Million
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $460,516 - $696,122	-27,428 Reduced 1.3%	2,082,973 $35.5 Million
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $53,736 - $102,807	4,401 Added 0.21%	2,110,401 $47.9 Million
Q3 2023 Nov 14, 2023	SELL	$11.84 - $18.65 $892,463 - $1.41 Million	-75,377 Reduced 3.46%	2,106,000 $32.1 Million
Q2 2023 Aug 14, 2023	SELL	$7.65 - $13.95 $2.09 Million - $3.81 Million	-273,250 Reduced 11.13%	2,181,377 $28.2 Million
Q1 2023 May 15, 2023	SELL	$7.08 - $12.62 $2.63 Million - $4.69 Million	-371,349 Reduced 13.14%	2,454,627 $20.3 Million
Q4 2022 Feb 14, 2023	BUY	$0.64 - $9.3 $1.81 Million - $26.3 Million	2,825,976 New	2,825,976 $26.1 Million

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.